newsfilter
← Latest News
GlobeNewswire·

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim